Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
- Conditions
- Lymphoma, T-Cell
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06699771
- Locations
- 🇰🇷
Seoul National University Hosptial, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 230
- Registration Number
- NCT06620510
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
- Conditions
- Breast CancerGastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06341647
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05258331
- Locations
- 🇰🇷
CHA Medical School Bundang CHA Medical Center, Gyeonggi-do, Korea, Republic of
🇰🇷Pusan national university hospital, Pusan, Korea, Republic of
🇰🇷Seoul national university hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
- Conditions
- Acute Respiratory Distress Syndrome
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- GC Cell Corporation
- Registration Number
- NCT05238532
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
🇰🇷Seoul national university boramae medical center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next